Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Tissue Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis


ABSTRACT: Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC). Whether E2 is tumorigenic or promotes expansion of undiagnosed pre-existing disease is unknown. To determine E2 effects on tumor promotion, we developed an intraperitoneal mouse xenograft model using ZsGreen fluorescent ER- 2008 and ER+ PEO4 human EOC cells. Tumor growth was quantified by in vivo fluorescent imaging. In ER+ tumors, E2 significantly increased size, induced progesterone receptors, and promoted lymph node metastasis, confirming that ER are functional and foster aggressiveness. Laser captured human EOC cells from ER- and ER+ xenografted tumors were profiled for expression of E2-regulated genes. Three classes of E-regulated EOC genes were defined, but less than 10% were shared with E-regulated breast cancer genes. Since breast cancer selective ER modulators (SERM) are therapeutically ineffective in EOC, we suggest that our EOC-specific E-regulated genes can assist pharmacologic discovery of ovarian targeted SERM. 15 samples were included in this experiment with a 2x2 factorial design with 2 different cell lines (2008 and PEO4) and 2 different hormone treatments (E for Estrogen and C for Placebo Control) and 4 replicates per treatment. 1 sample was excluded (a replicate of PEO4 with C treatment) because of poor quality.

ORGANISM(S): Homo sapiens

SUBMITTER: Monique Spillman 

PROVIDER: E-GEOD-22600 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Tissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasis.

Spillman Monique A MA   Manning Nicole G NG   Dye Wendy W WW   Sartorius Carol A CA   Post Miriam D MD   Harrell Joshua Chuck JC   Jacobsen Britta M BM   Horwitz Kathryn B KB  

Cancer research 20101019 21


Menopausal estrogen (E2) replacement therapy increases the risk of estrogen receptor (ER)-positive epithelial ovarian cancers (EOC). Whether E2 is tumorigenic or promotes expansion of undiagnosed preexisting disease is unknown. To determine E2 effects on tumor promotion, we developed an intraperitoneal mouse xenograft model using ZsGreen fluorescent ER(-) 2008 and ER(+) PEO4 human EOC cells. Tumor growth was quantified by in vivo fluorescent imaging. In ER(+) tumors, E2 significantly increased s  ...[more]

Similar Datasets

2011-05-13 | GSE22600 | GEO
2010-05-06 | E-GEOD-14518 | biostudies-arrayexpress
2015-06-13 | E-GEOD-69819 | biostudies-arrayexpress
2019-07-25 | GSE117940 | GEO
2009-02-03 | GSE14518 | GEO
2015-06-13 | GSE69819 | GEO
2019-07-25 | GSE117942 | GEO
2019-07-25 | GSE128911 | GEO
2019-06-26 | GSE116005 | GEO
2019-06-26 | GSE115481 | GEO